218 related articles for article (PubMed ID: 20735351)
1. Vascular endothelial growth factor (VEGF) in the pathogenesis of diabetic nephropathy of type 1 diabetes mellitus.
Mironidou-Tzouveleki M; Tsartsalis S; Tomos C
Curr Drug Targets; 2011 Jan; 12(1):107-14. PubMed ID: 20735351
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor (VEGF) and VEGF receptors in diabetic nephropathy: expression studies in biopsies of type 2 diabetic patients.
Bortoloso E; Del Prete D; Gambaro G; Dalla Vestra M; Sailer A; Baggio B; Antonucci F; Fioretto P; Anglani F
Ren Fail; 2001; 23(3-4):483-93. PubMed ID: 11499563
[TBL] [Abstract][Full Text] [Related]
3. Reducing VEGF-B Signaling Ameliorates Renal Lipotoxicity and Protects against Diabetic Kidney Disease.
Falkevall A; Mehlem A; Palombo I; Heller Sahlgren B; Ebarasi L; He L; Ytterberg AJ; Olauson H; Axelsson J; Sundelin B; Patrakka J; Scotney P; Nash A; Eriksson U
Cell Metab; 2017 Mar; 25(3):713-726. PubMed ID: 28190774
[TBL] [Abstract][Full Text] [Related]
4. Vascular Endothelial Growth Factor-A165b Is Protective and Restores Endothelial Glycocalyx in Diabetic Nephropathy.
Oltean S; Qiu Y; Ferguson JK; Stevens M; Neal C; Russell A; Kaura A; Arkill KP; Harris K; Symonds C; Lacey K; Wijeyaratne L; Gammons M; Wylie E; Hulse RP; Alsop C; Cope G; Damodaran G; Betteridge KB; Ramnath R; Satchell SC; Foster RR; Ballmer-Hofer K; Donaldson LF; Barratt J; Baelde HJ; Harper SJ; Bates DO; Salmon AH
J Am Soc Nephrol; 2015 Aug; 26(8):1889-904. PubMed ID: 25542969
[TBL] [Abstract][Full Text] [Related]
5. Deletion of pro-angiogenic factor vasohibin-2 ameliorates glomerular alterations in a mouse diabetic nephropathy model.
Masuda K; Tanabe K; Ujike H; Hinamoto N; Miyake H; Tanimura S; Sugiyama H; Sato Y; Maeshima Y; Wada J
PLoS One; 2018; 13(4):e0195779. PubMed ID: 29641565
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor in diabetic nephropathy.
Lenz T; Haak T; Malek J; Gröne HJ; Geiger H; Gossmann J
Kidney Blood Press Res; 2003; 26(5-6):338-43. PubMed ID: 14610338
[TBL] [Abstract][Full Text] [Related]
7. Effect of extract of Pueraria tuberosa on expression of hypoxia inducible factor-1α and vascular endothelial growth factor in kidney of diabetic rats.
Shukla R; Pandey N; Banerjee S; Tripathi YB
Biomed Pharmacother; 2017 Sep; 93():276-285. PubMed ID: 28648975
[TBL] [Abstract][Full Text] [Related]
8. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients.
Steinke JM; Mauer M;
Pediatr Endocrinol Rev; 2008 Aug; 5 Suppl 4():958-63. PubMed ID: 18806710
[TBL] [Abstract][Full Text] [Related]
9. Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy.
Hovind P; Tarnow L; Oestergaard PB; Parving HH
Kidney Int Suppl; 2000 Apr; 75():S56-61. PubMed ID: 10828763
[TBL] [Abstract][Full Text] [Related]
10. [The effects of VEGF-R inhibitor on podocytopathy of rats with type I diabetic nephropathy].
Wang S; Li Y; Huang YJ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Sep; 27(9):1003-6. PubMed ID: 21906476
[TBL] [Abstract][Full Text] [Related]
11. Association of Chemerin and Vascular Endothelial Growth Factor (VEGF) with Diabetic Nephropathy.
Lin S; Teng J; Li J; Sun F; Yuan D; Chang J
Med Sci Monit; 2016 Sep; 22():3209-14. PubMed ID: 27612613
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic angiogenesis by vascular endothelial growth factor supplementation for treatment of renal disease.
Logue OC; McGowan JW; George EM; Bidwell GL
Curr Opin Nephrol Hypertens; 2016 Sep; 25(5):404-9. PubMed ID: 27367910
[TBL] [Abstract][Full Text] [Related]
13. The natural drug DIAVIT is protective in a type II mouse model of diabetic nephropathy.
Stevens M; Neal CR; Craciun EC; Dronca M; Harper SJ; Oltean S
PLoS One; 2019; 14(3):e0212910. PubMed ID: 30865689
[TBL] [Abstract][Full Text] [Related]
14. Quantitave and qualitative changes in vascular endothelial growth factor gene expression in glomeruli of patients with type 2 diabetes.
Bortoloso E; Del Prete D; Dalla Vestra M; Gambaro G; Saller A; Antonucci F; Baggio B; Anglani F; Fioretto P
Eur J Endocrinol; 2004 Jun; 150(6):799-807. PubMed ID: 15191350
[TBL] [Abstract][Full Text] [Related]
15. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody.
Flyvbjerg A; Dagnaes-Hansen F; De Vriese AS; Schrijvers BF; Tilton RG; Rasch R
Diabetes; 2002 Oct; 51(10):3090-4. PubMed ID: 12351452
[TBL] [Abstract][Full Text] [Related]
16. Stability and Species Specificity of Renal VEGF-A Splicing Patterns in Kidney Disease.
Turner RJ; Eikmans M; Bajema IM; Bruijn JA; Baelde HJ
PLoS One; 2016; 11(9):e0162166. PubMed ID: 27598902
[TBL] [Abstract][Full Text] [Related]
17. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology.
Schrijvers BF; Flyvbjerg A; De Vriese AS
Kidney Int; 2004 Jun; 65(6):2003-17. PubMed ID: 15149314
[TBL] [Abstract][Full Text] [Related]
18. The VEGF-A inhibitor sFLT-1 improves renal function by reducing endothelial activation and inflammation in a mouse model of type 1 diabetes.
Bus P; Scharpfenecker M; Van Der Wilk P; Wolterbeek R; Bruijn JA; Baelde HJ
Diabetologia; 2017 Sep; 60(9):1813-1821. PubMed ID: 28620823
[TBL] [Abstract][Full Text] [Related]
19. Correlation Analysis of Vascular Endothelial Growth Factor Level with Clinicopathological Features and Prognosis in Patients with Diabetic Nephropathy: A Biopsy-based Study.
Zhang J; Zhu H; Tang Q; Wu J
Cell Mol Biol (Noisy-le-grand); 2023 Aug; 69(8):192-197. PubMed ID: 37715389
[TBL] [Abstract][Full Text] [Related]
20. Cellular and molecular aspects of diabetic nephropathy; the role of VEGF-A.
Carranza K; Veron D; Cercado A; Bautista N; Pozo W; Tufro A; Veron D
Nefrologia; 2015; 35(2):131-8. PubMed ID: 26300505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
